Background: The Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical myxomatous mitral valve disease (EPIC) study monitored dogs with myxomatous mitral valve disease (MMVD) as they developed congestive heart failure (CHF).
Objectives: To describe the changes in clinical and radiographic variables occurring as dogs with MMVD and cardiomegaly develop CHF, compared to similar dogs that do not develop CHF.
Animals: One hundred and thirty-five, and 73 dogs that did or did not develop CHF, respectively.
Materials and methods: The following variables were evaluated in 2 groups of dogs (dogs that did or did not develop CHF): Heart rate (HR), clinic respiratory rate (RR), home-measured resting respiratory rate (RRR), rectal temperature (RT), body weight (BW), and vertebral heart sum (VHS). Absolute value and rate of change of each variable were calculated for each day a dog was in study. Daily means were calculated and plotted against time. The onset of CHF or last visit before leaving the study were set as reference time points.
Results: The most extreme values and rate of change occurred in variables immediately before onset of CHF. Vertebral heart sum increased earliest. Heart rate, RR, and RRR also increased. Rectal temperature and BW decreased. Increases in RR and RRR were most extreme and occurred immediately before CHF.
Conclusions and clinical importance: Dogs with MMVD and cardiomegaly experience increases in HR, RR, RRR, and VHS, and decreases in BW and RT as they develop CHF. The variables with highest absolute change and rate of change were RR and RRR. These findings reinforce the value of RR and RRR as indicators of impending or incipient CHF.
Keywords: canine; cardiovascular; clinical epidemiology; clinical trials; heart failure; physical examination; radiology and diagnostic imaging.
© 2020 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.J Vet Intern Med. 2018 Jan;32(1):72-85. doi: 10.1111/jvim.14885. Epub 2017 Dec 6. J Vet Intern Med. 2018. PMID: 29214723 Free PMC article. Clinical Trial.
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.J Vet Intern Med. 2016 Nov;30(6):1765-1779. doi: 10.1111/jvim.14586. Epub 2016 Sep 28. J Vet Intern Med. 2016. PMID: 27678080 Free PMC article. Clinical Trial.
Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.J Vet Intern Med. 2013 Nov-Dec;27(6):1441-51. doi: 10.1111/jvim.12181. Epub 2013 Sep 6. J Vet Intern Med. 2013. PMID: 24010489 Clinical Trial.
An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.J Small Anim Pract. 2009 Sep;50 Suppl 1:25-33. doi: 10.1111/j.1748-5827.2009.00800.x. J Small Anim Pract. 2009. PMID: 19765217 Review.
Canine degenerative myxomatous mitral valve disease: natural history, clinical presentation and therapy.Vet Clin North Am Small Anim Pract. 2010 Jul;40(4):651-63. doi: 10.1016/j.cvsm.2010.03.008. Vet Clin North Am Small Anim Pract. 2010. PMID: 20610017 Review.
- Boswood A, Gordon SG, Haggstrom J, et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving Pimobendan or placebo: the EPIC study. J Vet Intern Med. 2018;32:72-85.
- Boswood A, Haggstrom J, Gordon SG, et al. Effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly: the EPIC study-a randomized clinical trial. J Vet Intern Med. 2016;30:1765-1779.
- Lord PF, Hansson K, Carnabuci C, Kvart C, Häggström J. Radiographic heart size and its rate of increase as tests for onset of congestive heart failure in Cavalier King Charles Spaniels with mitral valve regurgitation. J Vet Intern Med. 2011;25:1312-1319.
- Lord P, Hansson K, Kvart C, Häggström J. Rate of change of heart size before congestive heart failure in dogs with mitral regurgitation. J Small Anim Pract. 2010;51:210-218.
- Hezzell MJ, Boswood A, Moonarmart W, Elliott J. Selected echocardiographic variables change more rapidly in dogs that die from myxomatous mitral valve disease. J Vet Cardiol. 2012;14:269-279.